KPL-914
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Pericarditis
Conditions
Recurrent Pericarditis
Trial Timeline
Jan 24, 2018 → May 17, 2019
NCT ID
NCT03980522About KPL-914
KPL-914 is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Recurrent Pericarditis. The current trial status is completed. This product is registered under clinical trial identifier NCT03980522. Target conditions include Recurrent Pericarditis.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Pericarditis were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03980522 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Pericarditis